2026 Annual Meeting | Industry Therapeutic Update from C2N Diagnostics: Diagnostic Precision in Alzheimer's Disease: A Discussion on the Clinical Integration of Blood Biomarker Testing

�鶹��ýӳ��

2026 Annual Meeting | Industry Therapeutic Update from C2N Diagnostics: Diagnostic Precision in Alzheimer's Disease: A Discussion on the Clinical Integration of Blood Biomarker Testing

Date Tuesday 04/21/26

Time 06:00 PM - 08:00 PM CDT Add To Calendar

Location Hyatt Regency McCormick Place Chicago | Regency CDE

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives This program brings together clinicians to discuss current and emerging innovations in Alzheimer's disease diagnostics, with a focus on blood-based tests in clinical practice. The speakers will examine the role of blood tests can provide for identifying amyloid pathology and considerations for utilization in diagnostic evaluation. The session will highlight opportunities for blood tests in Alzheimer's disease assessment, current approaches to clinical decision-making, and practical perspectives on diagnosing Alzheimer's.

Reception: 5:30 PM Program: 6:00–7:00 PM

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM CDT	Speaker	Industry Therapeutic Update from C2N Diagnostics: Diagnostic Precision in Alzheimer's Disease: A Discussion on the Clinical Integration of Blood Biomarker Testing

Faculty Disclosures
Joel Braunstein	Dr. Braunstein has received personal compensation for serving as an employee of C2N Diagnostics. Dr. Braunstein has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for C2N Diagnositcs.